1. Home
  2. DNLI vs ESGR Comparison

DNLI vs ESGR Comparison

Compare DNLI & ESGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNLI
  • ESGR
  • Stock Information
  • Founded
  • DNLI 2013
  • ESGR 2001
  • Country
  • DNLI United States
  • ESGR Bermuda
  • Employees
  • DNLI N/A
  • ESGR N/A
  • Industry
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • ESGR Property-Casualty Insurers
  • Sector
  • DNLI Health Care
  • ESGR Finance
  • Exchange
  • DNLI Nasdaq
  • ESGR Nasdaq
  • Market Cap
  • DNLI 4.5B
  • ESGR 4.7B
  • IPO Year
  • DNLI 2017
  • ESGR N/A
  • Fundamental
  • Price
  • DNLI $25.05
  • ESGR $323.65
  • Analyst Decision
  • DNLI Strong Buy
  • ESGR
  • Analyst Count
  • DNLI 11
  • ESGR 0
  • Target Price
  • DNLI $38.90
  • ESGR N/A
  • AVG Volume (30 Days)
  • DNLI 788.0K
  • ESGR 60.7K
  • Earning Date
  • DNLI 11-06-2024
  • ESGR 11-12-2024
  • Dividend Yield
  • DNLI N/A
  • ESGR N/A
  • EPS Growth
  • DNLI N/A
  • ESGR 51.73
  • EPS
  • DNLI N/A
  • ESGR 66.06
  • Revenue
  • DNLI N/A
  • ESGR $1,067,000,000.00
  • Revenue This Year
  • DNLI N/A
  • ESGR N/A
  • Revenue Next Year
  • DNLI $283.75
  • ESGR N/A
  • P/E Ratio
  • DNLI N/A
  • ESGR $4.90
  • Revenue Growth
  • DNLI 204.74
  • ESGR 17.90
  • 52 Week Low
  • DNLI $14.56
  • ESGR $258.11
  • 52 Week High
  • DNLI $33.33
  • ESGR $348.48
  • Technical
  • Relative Strength Index (RSI)
  • DNLI 37.93
  • ESGR 54.48
  • Support Level
  • DNLI $26.17
  • ESGR $323.27
  • Resistance Level
  • DNLI $33.33
  • ESGR $325.94
  • Average True Range (ATR)
  • DNLI 1.64
  • ESGR 1.71
  • MACD
  • DNLI -0.13
  • ESGR -0.09
  • Stochastic Oscillator
  • DNLI 0.66
  • ESGR 62.01

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

About ESGR Enstar Group Limited

Enstar Group Ltd is a (re)insurance group that offers capital release solutions through its network of group companies. It seeks to create value by managing (re)insurance companies and portfolios of (re)insurance and other liability businesses in run-off and striving to generate an attractive risk-adjusted return from its investment portfolio. Its operations are through four reportable segments: Run-off, Assumed Life, Investments, and Legacy Underwriting.

Share on Social Networks: